Advertisement

Topics

Vectura Group plc Strategy, SWOT and Corporate Finance Report [Report Updated: 28072018] Prices from USD $175

06:18 EDT 28 Sep 2018 | BioPortfolio Reports

Vectura Group plc Strategy, SWOT and Corporate Finance Report


Summary


Vectura Group plc Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.


Key Highlights


Vectura Group plc Vectura or 'the group' is engaged in the development of pharmaceutical therapies for the treatment of airwaysrelated diseases. It develops inhalation products to diseases such as obstructive pulmonary disease COPD, cystic fibrosis, asthma, chronic pulmonary fibrosis and other diseases. It offers dry powder inhalers DPIs, pressurized metered dose inhaler pMDI and smart nebulizer delivery systems. The group's portfolio is comprised of partnered and licensed marketed products as well as branded and generic investigational drugs. The group operates in the US, the UK and other European countries. It is headquartered in Wiltshire, UK.


Scope


Detailed information on Vectura Group plc required for business and competitor intelligence needs

A study of the major internal and external factors affecting Vectura Group plc in the form of a SWOT analysis

An indepth view of the business model of Vectura Group plc including a breakdown and examination of key business segments

Intelligence on Vectura Group plc's mergers and acquisitions MandA, strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

News about Vectura Group plc, such as business expansion, restructuring, and contract wins

Large number of easytograsp charts and graphs that present important data and key trends


Reasons to buy


Gain understanding of Vectura Group plc and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Vectura Group plc as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Vectura Group plc's business structure, strategy and prospects.

Original Article: Vectura Group plc Strategy, SWOT and Corporate Finance Report [Report Updated: 28072018] Prices from USD $175

NEXT ARTICLE

More From BioPortfolio on "Vectura Group plc Strategy, SWOT and Corporate Finance Report [Report Updated: 28072018] Prices from USD $175"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

Cystic Fibrosis
Affecting over 8,500 people in the UK, Cystic Fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. Around half of the CF population can expect to live over 38 years, although improvements in treatments mean a baby born ...